Jiangsu Yuyue Medical Equipment & Supply Co Ltd

Nanjing University Environment's controlling shareholder plans to transfer no less than 15% of the company's total share capital through public solicitation of transferees by agreement. The completion of the transfer may lead to a change in the company's controlling shareholder and actual controller. Ben Chuan Intelligent plans for the company and its wholly owned subsidiary Zhuhai Shuohong to invest a total of no more than 3 billion yuan to expand high-end PCB capacity in Nanjing and Zhuhai. The Nanjing project has a planned total investment of about 2 billion yuan to build an industrial project with annual output of 1.5 million square meters of AI computing high-multilayer and high-order HDI circuit boards. The Zhuhai project plans to invest no more than 1 billion yuan to implement the Zhuhai Shuohong Phase II multilayer high-end interconnect products South China intelligent manufacturing base project. In addition, Zhifei Biological's controlling subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. has had its application for production registration of semaglutide injection accepted by the National Medical Products Administration. Changgao Electric's four subsidiaries won a total of 299 million yuan in State Grid bidding, accounting for 17.96% of the company's 2025 consolidated operating revenue. Zhou Jinyi, a person acting in concert with the controlling shareholder of Asia-Pacific Technology, plans to increase his shareholding in the company by no less than 50 million yuan and no more than 100 million yuan. Guangyi Investment, a person acting in concert with the actual controller of Hangzhou Kelin, plans to increase its shareholding in the company by no less than 25 million yuan and no more than 50 million yuan. Yuwell Medical plans to repurchase company shares worth no less than 200 million yuan and no more than 400 million yuan.

Yuwell Medical announced that it has received the Medical Device Registration Certificate for its wrist ambulatory blood pressure monitor from the Jiangsu Medical Products Administration. The product includes multiple models and is intended for measuring systolic pressure, diastolic pressure, and pulse rate in adults at rest, with the values provided for clinical reference. The device features single blood pressure measurement, 24-hour ambulatory blood pressure measurement, and nighttime blood pressure monitoring, capable of recording blood pressure data and trends. It also monitors health parameters such as heart rate, blood oxygen, stress, and sleep, aiming to assist users in daily health management.

Yuwell Medical's holding subsidiary, Primedic Jiangsu Medical Technology, has obtained a Medical Device Registration Certificate from the National Medical Products Administration for its semi-automatic external defibrillator. The certified products include multiple models such as HeartSave HP-C1 and HeartSave HP-C6, suitable for cardiopulmonary resuscitation and defibrillation therapy, and can be used in public places, homes, and medical settings. In the first quarter of 2026, Yuwell Medical achieved revenue of 2.37 billion yuan and a net profit attributable to the parent company of 428 million yuan.